Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utreglutide for non-alcoholic fatty liver disease in obese adults
ACTRN12624000322538Phase 2Completed
- Sponsor
- International Sponsor: Sun Pharmaceutical Industries Ltd
- Start
- Mar 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of utreglutide in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by International Sponsor: Sun Pharmaceutical Industries Ltd. Started Mar 2024; status: completed.
02
Drugs
utreglutide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ACTRN12624000322538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000322538.